精神分裂症脑谷氨酸水平的变异性与幅度:一项meta与mega分析
该研究通过meta分析和mega分析,纳入123项1H-MRS研究(8256例患者,7532名对照),评估精神分裂症患者脑谷氨酸能代谢物的变异性与均值差异。结果显示患者在内侧额叶皮层、背外侧前额叶皮层和丘脑的谷氨酸能代谢物变异性大于对照,且多数个体数据呈单峰分布;均值差异表现为内侧额叶皮层谷氨酸降低、丘脑谷氨酰胺升高和基底节Glx升高。
要点
- 患者内侧额叶皮层谷氨酸、谷氨酰胺和Glx的变异性均显著大于对照。
- 患者丘脑谷氨酰胺和Glx以及基底节Glx均值显著高于对照。
- 患者内侧额叶皮层谷氨酸均值显著低于对照。
核心结论
- 精神分裂症患者多个脑区谷氨酸能代谢物存在更大的个体间变异性,同时部分脑区均值存在差异。
研究设计与样本
- 检索MEDLINE和EMBASE至2022年9月,纳入123项报告精神分裂症谷氨酸、谷氨酰胺或Glx的1H-MRS研究,共8256例患者和7532名对照。
主要发现
- 内侧额叶皮层谷氨酸CVR=0.15(p<0.001)、谷氨酰胺CVR=0.15(p=0.003)、Glx CVR=0.11(p=0.002)。
- 背外侧前额叶皮层谷氨酰胺CVR=0.14(p=0.05)、Glx CVR=0.25(p<0.001)。
- 丘脑谷氨酸CVR=0.16(p=0.008)、Glx CVR=0.19(p=0.008)。
- 均值差异:内侧额叶皮层谷氨酸g=-0.15(p=0.03),丘脑谷氨酰胺g=0.53(p<0.001),基底节Glx g=0.28(p<0.001)。
关键数值与推荐
- 年轻且症状更重的患者研究关联基底节谷氨酸变异性更大(年龄z=-0.03,p=0.003;症状z=0.007,p=0.02)。
- 年长且症状更重的患者研究关联内侧额叶皮层谷氨酸变异性更大(年龄z=0.01,p=0.02;谷氨酰胺与症状z=0.01,p=0.02)。
- 男性比例与内侧额叶皮层谷氨酸SMD负相关(z=-0.02,p<0.001)。
- PANSS总分与基底节谷氨酸SMD正相关(z=0.01,p=0.01),与颞叶谷氨酸SMD正相关(z=0.05,p=0.008)。
临床怎么用
- 谷氨酸能代谢物变异性可能有助于识别精神分裂症患者亚组,为未来治疗策略提供参考。
局限性
- 多数个体患者数据呈单峰分布,提示变异性增加并非由明显双峰亚组驱动。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glutamatergic dysfunction is implicated in schizophrenia pathoaetiology, but this may vary in extent between patients. It is unclear whether inter-individual variability in glutamate is greater in schizophrenia than the general population. We conducted meta-analyses to assess (1) variability of glutamate measures in patients relative to controls (log coefficient of variation ratio: CVR); (2) standardised mean differences (SMD) using Hedges g; (3) modal distribution of individual-level glutamate data (Hartigan's unimodality dip test). MEDLINE and EMBASE databases were searched from inception to September 2022 for proton magnetic resonance spectroscopy (1H-MRS) studies reporting glutamate, glutamine or Glx in schizophrenia. 123 studies reporting on 8256 patients and 7532 controls were included. Compared with controls, patients demonstrated greater variability in glutamatergic metabolites in the medial frontal cortex (MFC, glutamate: CVR = 0.15, p < 0.001; glutamine: CVR = 0.15, p = 0.003; Glx: CVR = 0.11, p = 0.002), dorsolateral prefrontal cortex (glutamine: CVR = 0.14, p = 0.05; Glx: CVR = 0.25, p < 0.001) and thalamus (glutamate: CVR = 0.16, p = 0.008; Glx: CVR = 0.19, p = 0.008). Studies in younger, more symptomatic patients were associated with greater variability in the basal ganglia (BG glutamate with age: z = -0.03, p = 0.003, symptoms: z = 0.007, p = 0.02) and temporal lobe (glutamate with age: z = -0.03, p = 0.02), while studies with older, more symptomatic patients associated with greater variability in MFC (glutamate with age: z = 0.01, p = 0.02, glutamine with symptoms: z = 0.01, p = 0.02). For individual patient data, most studies showed a unimodal distribution of glutamatergic metabolites. Meta-analysis of mean differences found lower MFC glutamate (g = -0.15, p = 0.03), higher thalamic glutamine (g = 0.53, p < 0.001) and higher BG Glx in patients relative to controls (g = 0.28, p < 0.001). Proportion of males was negatively associated with MFC glutamate (z = -0.02, p < 0.001) and frontal white matter Glx (z = -0.03, p = 0.02) in patients relative to controls. Patient PANSS total score was positively associated with glutamate SMD in BG (z = 0.01, p = 0.01) and temporal lobe (z = 0.05, p = 0.008). Further research into the mechanisms underlying greater glutamatergic metabolite variability in schizophrenia and their clinical consequences may inform the identification of patient subgroups for future treatment strategies.
引用
- Merritt K, McCutcheon RA, Aleman A, et al. Variability and magnitude of brain glutamate levels in schizophrenia: a meta and mega-analysis. Mol Psychiatry. 2023. PMID: 36806762. doi:10.1038/s41380-023-01991-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。